[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TN2019000004A1 - Vita, chemotherapy treatment for several types of cancer and without major and moderate side effects. - Google Patents

Vita, chemotherapy treatment for several types of cancer and without major and moderate side effects.

Info

Publication number
TN2019000004A1
TN2019000004A1 TNP/2019/000004A TN2019000004A TN2019000004A1 TN 2019000004 A1 TN2019000004 A1 TN 2019000004A1 TN 2019000004 A TN2019000004 A TN 2019000004A TN 2019000004 A1 TN2019000004 A1 TN 2019000004A1
Authority
TN
Tunisia
Prior art keywords
cancer
treatment
formula
vita
major
Prior art date
Application number
TNP/2019/000004A
Other languages
French (fr)
Inventor
Ghidhaoui Abir
Original Assignee
Ghidhaoui Abir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ghidhaoui Abir filed Critical Ghidhaoui Abir
Priority to TNP/2019/000004A priority Critical patent/TN2019000004A1/en
Priority to PCT/TN2019/000008 priority patent/WO2020145905A1/en
Publication of TN2019000004A1 publication Critical patent/TN2019000004A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La combinaison innovante des différents agents biologiques a permis l'élaboration d'une formule traitante sous forme de perfusion intraveineuse, pour le traitement de six (6) types de cancer qui sont : Le cancer du tissu mammaire Le cancer de l'ovaire Le cancer de la prostate Le cancer de l'estomac Le cancer de la vessie La procédure d'expérimentation était préparée durant 40 mois. L'expérimentation de la formule était réalisée en comparaison avec le traitement «cisplatine» de MYLAN et le traitement «5-fluouracile» de TEVA. Ce traitement est favorisé par rapport les autres traitements sur le marché car il assure la provocation de la procédure de la mort cellulaire des cellules cancéreuse durant une durée plus courte que la durée de la mort cellulaire en utilisant les autres formules. Aussi, la formulation de VITA provoque l'apoptose cellulaire «sélectif» sans les effets negatifs majeurs et moyens. Cette formule est destinée strictement pour l'industrie pharmaceutique.The innovative combination of different biological agents has made it possible to develop a treatment formula in the form of an intravenous infusion, for the treatment of six (6) types of cancer which are: Cancer of the mammary tissue Cancer of the ovary Cancer of the prostate Stomach cancer Bladder cancer The experimental procedure was prepared for 40 months. The experiment with the formula was carried out in comparison with the “cisplatin” treatment from MYLAN and the “5-fluouracil” treatment from TEVA. This treatment is favored over other treatments in the market because it ensures the provocation of the cell death procedure of cancer cells for a shorter time than the time of cell death using the other formulas. Also, the formulation of VITA causes "selective" cell apoptosis without major and moderate negative effects. This formula is intended strictly for the pharmaceutical industry.

TNP/2019/000004A 2019-01-08 2019-01-08 Vita, chemotherapy treatment for several types of cancer and without major and moderate side effects. TN2019000004A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TNP/2019/000004A TN2019000004A1 (en) 2019-01-08 2019-01-08 Vita, chemotherapy treatment for several types of cancer and without major and moderate side effects.
PCT/TN2019/000008 WO2020145905A1 (en) 2019-01-08 2019-02-19 Vita, the chemotherapy treatment for several types of cancer and without major and moderate side effects

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TNP/2019/000004A TN2019000004A1 (en) 2019-01-08 2019-01-08 Vita, chemotherapy treatment for several types of cancer and without major and moderate side effects.

Publications (1)

Publication Number Publication Date
TN2019000004A1 true TN2019000004A1 (en) 2020-07-15

Family

ID=66484117

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP/2019/000004A TN2019000004A1 (en) 2019-01-08 2019-01-08 Vita, chemotherapy treatment for several types of cancer and without major and moderate side effects.

Country Status (2)

Country Link
TN (1) TN2019000004A1 (en)
WO (1) WO2020145905A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030068205A (en) * 2001-01-09 2003-08-19 메르크 파텐트 게엠베하 Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
US20060293264A1 (en) * 2004-07-22 2006-12-28 Grandis Jennifer R STAT3 decoy oligonucleotides and uses therefor
WO2008013966A2 (en) * 2006-07-28 2008-01-31 Johns Hopkins University Use of 8-quinolinol and its analogs to target cancer stem cells

Also Published As

Publication number Publication date
WO2020145905A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
Ito et al. The development of carcinoma in liver of rats treated with m-toluylenediamine and the synergistic and antagonistic effects with other chemicals
Banerjee et al. Efficacy of selected natural products as therapeutic agents against cancer
CN104042618B (en) The treatment of malignant hematologic disease
De Angelis et al. SIRT1 activation rescues doxorubicin-induced loss of functional competence of human cardiac progenitor cells
US20210338686A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
McNabb et al. Ultrasound-stimulated microbubble radiation enhancement of tumors: Single-dose and fractionated treatment evaluation
CN109906081A (en) Utilize the combination cancer therapy of pentaaza big ring complex compound and Vitamin C acid compounds
Franks et al. The effect of sex hormones on the growth of HeLa tumour nodules in male and female mice
TN2019000004A1 (en) Vita, chemotherapy treatment for several types of cancer and without major and moderate side effects.
CN1681489A (en) Combination of chemotherapeutic drugs for increasing antitumor activity
Iwaki et al. Intra-arterial Chemotherapy With Concomitant Use of Vasoconstrictors for Liver Cancer ¹
TWI768686B (en) Combination drug composition for anti-double hit lymphoma and application thereof
CN109419803A (en) Cell autophagy inhibitor and Afatinib pharmaceutical composition and its purposes in preparation tumour Synergistic preparations
EA014603B1 (en) Anti-tumoral, antibacterial and antiviral pharmaceutical composition (variants)
CN104640538B (en) Composition comprising NDGA derivatives and Sorafenib and its purposes in treating cancer
JPWO2019107341A1 (en) Ozone nanobubble anticancer drug
JPS60501408A (en) Methods and agents for increasing animal tolerance to oxidant stress-inducing antibiotics
KR20150083353A (en) Pharmaceutical composition for prevention or treatment of bladder tumor via intravesical instillation
Dréau et al. Inhibitory effects of fusarochromanone on melanoma growth
Tabaru et al. Treatment of VX2 carcinoma implanted in the liver with arterial and intraperitoneal administration of oily anticancer agents.
CN1972955B (en) Radiosensitizer
Ning et al. Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo
ES2415907T3 (en) Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
Shafik Intratunical injection of methotrexate for the treatment of seminoma of the testicle
KR20210039413A (en) Combination therapy for the treatment of cancer